Clavis Pharma appoints Interim Chairman and Acting CEO

CFO Gunnar Manum will be Acting CEO until long-term solution is found

Clavis Pharma, a Norwegian cancer drug development company, has appointed Martin Nes, a member of the Board of Directors, as Interim Chairman. He replaces Anders Wiklund, who resigned from the Board on 21 May.

The Oslo-based company has also appointed Gunnar Manum, Chief Financial Officer, to the additional position of Acting CEO, until a long-term solution is found.

You may also like

Regulatory

Anticancer agent – elacytarabine

Cytarabine can cross the blood–brain barrier and is useful in the treatment of CNS lymphomas, but the response is variable and resistance commonly develops
Regulatory

Leukaemia treatment gains fast track designation

Clavis Pharma’s elacytarabine currently in Phase III trial
Research & Development

Amolyt receives FDA fast track designation for hypoparathyroidism drug

The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Manufacturing

Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies

Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
Subscribe now